SS-31 (Elamipretide): The Mitochondrial Peptide Repairing the Cell's Power Grid

At a Glance

Mitochondrial dysfunction underlies aging, heart failure, chronic kidney disease, and a growing list of complex chronic illnesses seen in integrative medicine. Yet most clinical interventions — CoQ10, NAD precursors, PQQ — act upstream of the electron transport chain, improving substrate supply without directly repairing the structural damage that derails ATP synthesis in the first place.

SS-31 takes a different approach. Rather than flooding the system with cofactors, this four-amino-acid peptide travels directly to the inner mitochondrial membrane (IMM), binds the phospholipid cardiolipin, and physically restores the architecture that makes efficient oxidative phosphorylation possible. The result, in preclinical and now human trials, is a measurable improvement in cellular energy output — without the toxicity concerns that have hobbled earlier mitochondria-targeted strategies.

What Is SS-31 and Why Does It Work?

SS-31 belongs to the Szeto-Schiller (SS) family of peptides, developed by Hazel Szeto, M.D., Ph.D., at Cornell. It is a synthetic tetrapeptide with the sequence D-Arg–Dmt–Lys–Phe-NH₂, where Dmt stands for 2′,6′-dimethyltyrosine, a non-natural amino acid that confers both stability and selective affinity for anionic phospholipids.

Cardiolipin: The Structural Keystone

Cardiolipin (CL) is a unique phospholipid found almost exclusively in the IMM. It comprises roughly 20% of IMM phospholipid content and plays three roles critical to bioenergetics:

1. Cristae curvature. CL stabilises the tight folds of the IMM (cristae) where ATP synthase and cytochrome bc1 complexes are densely packed. Disrupted CL flattens cristae and physically separates respiratory supercomplexes.
2. Supercomplex integrity. Respiratory chain proteins — Complexes I, III, and IV — organise into supercomplexes (“respirasomes”) that channel electrons with minimal leak. CL is the structural glue holding these assemblies together.
3. Electron carrier stabilisation. Cytochrome c associates with CL via electrostatic interactions. Oxidised CL releases cytochrome c, which then signals apoptosis and diverts electrons toward superoxide rather than ATP synthesis.

In aging, ischaemia, inflammation, and metabolic disease, CL undergoes peroxidation — oxidative damage that progressively collapses mitochondrial architecture and reduces respiratory efficiency.

How SS-31 Repairs the System

SS-31’s alternating aromatic/cationic motif (similar to CL-binding antimicrobial peptides) allows it to accumulate ~1,000-fold in mitochondria relative to cytoplasm. It then:

• Intercalates with CL at the IMM, reducing CL peroxidation by physically preventing cardiolipin–cytochrome c interactions that generate lipid radical propagation chains.
• Reshapes cristae. By stabilising CL, SS-31 restores cristae architecture, brings respiratory supercomplexes back into proximity, and reduces the path length electrons must travel.
• Reduces Complex I–III electron leak. Tighter supercomplex packing minimises the probability of single-electron transfer to oxygen, cutting superoxide production at the source rather than scavenging it downstream.

The net outcome is improved state 3 respiration (ADP-stimulated ATP production), lower baseline ROS generation, and — in stressed cells — reduced propensity for apoptosis initiation through the intrinsic pathway.

Clinical Evidence

Heart Failure with Preserved Ejection Fraction (HFpEF)

HFpEF accounts for roughly half of all heart failure cases and lacks FDA-approved disease-modifying therapies. Mitochondrial dysfunction in cardiomyocytes is a central feature: impaired fatty acid oxidation, reduced ETC efficiency, and elevated ROS all contribute to diastolic stiffness.

The SERCA-LVEF trial (Sabbah et al.) demonstrated that SS-31 infusion over 4 weeks improved left ventricular end-systolic volume and 6-minute walk distance versus placebo in patients with ejection fractions ≥40%. The MMTT (mitochondrial membrane target trial) extended these findings to patients with EF ≥50%, showing significant improvement in cardiac energetics by phosphocreatine-to-ATP ratio (PCr/ATP) measured by ³¹P-MRS — a direct indicator of in vivo cardiac mitochondrial function.

A 2023 pilot trial (n=47) reported that 28-day subcutaneous SS-31 at 40 mg/day improved composite Kansas City Cardiomyopathy Questionnaire scores and reduced NT-proBNP by ~18% versus baseline. These are preliminary numbers, but they establish signal in a notoriously difficult indication.

Acute Kidney Injury and Renal Ischaemia

The kidney is among the most metabolically active organs and is correspondingly vulnerable to mitochondrial compromise during ischaemia-reperfusion (I-R). Multiple animal models show SS-31 administered before or immediately after I-R substantially reduces tubular cell necrosis, preserves GFR, and limits subsequent CKD progression.

In a Phase I/II human trial (ROMIO: Renal Outcomes in Mitochondrial Injury from Organ transplantation), patients receiving deceased-donor kidneys were randomised to SS-31 or placebo donor pretreatment. The SS-31 group showed faster creatinine recovery at 7 days and reduced incidence of delayed graft function — a clinically meaningful endpoint given DGF’s association with chronic rejection.

Primary Mitochondrial Myopathy (MMPOWER Study)

The MMPOWER-3 trial (elamipretide versus placebo, n=218) remains the largest SS-31 dataset. Patients with confirmed mitochondrial myopathy received 40 mg SQ daily for 24 weeks. The primary endpoint — distance walked on 6MWT — missed significance in the intent-to-treat population (–18 m difference, p=0.08). However, pre-specified analyses of patients with lower baseline function and longer disease duration showed meaningful benefit, and the long-term extension showed sustained improvement over 144 weeks of open-label use.

The trial’s results underscore a recurring challenge in mitochondrial medicine: heterogeneous patient populations (diverse genetic defects, variable energy demands) dilute treatment effects in aggregate analyses even when specific subgroups benefit substantially.

Aging, Sarcopenia, and Frailty

Animal aging models consistently demonstrate that SS-31 reverses age-related mitochondrial dysfunction in skeletal muscle, heart, and kidney. In aged mice, 8-week SS-31 treatment restored mitochondrial cristae density, reduced oxidative damage markers, and improved grip strength and running capacity to levels seen in middle-aged controls.

Human data in aging specifically are limited to Phase I safety work, but the mechanistic rationale is strong: the same cardiolipin peroxidation that drives disease pathology is a hallmark of normal mitochondrial aging.

Dosing and Administration

All current human-trial data used subcutaneous injection of sterile lyophilised elamipretide reconstituted in saline. The standard Phase III dose was 40 mg/day administered as a 40-minute subcutaneous infusion using a syringe pump. Some cardiomyopathy trials used a 40 mg/4h IV infusion format.

Investigational Dosing Framework

In clinical research contexts, the 40 mg flat dose (approximately 0.5 mg/kg for an 80 kg person) is the most studied. Duration in trials ranged from 4 to 144 weeks. No formal pharmacokinetic accumulation has been observed; half-life is approximately 2–4 hours in humans, supporting once-daily administration.

Route Considerations

SS-31 is rapidly cleared via renal filtration when given IV. SQ administration produces a slower absorption profile and may improve tissue distribution. Oral bioavailability is negligible due to rapid peptidase degradation in the GI tract.

Patient Selection and Clinical Indications

Based on available evidence, the patients most likely to benefit are those with demonstrable mitochondrial dysfunction as a primary or major contributing mechanism. Candidate conditions include:

• Heart failure with preserved EF (particularly with evidence of reduced PCr/ATP or impaired cardiac energetics)
• Post-ischaemic renal injury (transplant recipients, contrast-induced AKI, post-cardiac-surgery AKI)
• Genetically confirmed mitochondrial myopathy (MELAS, MERRF, Kearns-Sayre — noting the heterogeneous trial results)
• Age-related frailty and sarcopenia with mitochondrial dysfunction biomarkers
• Chronic fatigue states where mitochondrial testing (ATP production assays, organic acid testing) confirms functional compromise
• Post-COVID mitochondrial dysfunction — a growing area of interest given the convergent evidence of Complex I impairment in long-COVID

Who Should NOT Receive SS-31

• Pregnancy and lactation: no safety data; avoid
• Known hypersensitivity to any component of the peptide or excipients
• Severe hepatic impairment: pharmacokinetics unstudied
• Concurrent strong mitochondrial toxins (e.g., linezolid, some antiretrovirals, statins at high dose in patients with pre-existing myopathy): additive risk is theoretical but warrants caution
• Patients with haematologic malignancy or active systemic infection: immunomodulatory effects of restored mitochondrial function on immune cell activation are incompletely understood

How SS-31 Differs from Other Mitochondrial Agents

SS-31 is the only agent in this group that directly addresses the structural collapse of the IMM rather than providing upstream substrates or downstream antioxidants. This makes it complementary to, rather than competitive with, NAD precursors and CoQ10 — agents that improve substrate availability benefit most when the machinery that uses those substrates is structurally intact.

Monitoring and Biomarkers

Because ATP production cannot be measured directly in clinical practice, surrogate markers guide monitoring:

• Serum lactate: elevated lactate-to-pyruvate ratio suggests ETC bottleneck; improvement indicates restored Complex I/III flux
• Cardiopulmonary exercise testing (CPET): VO₂ peak and ventilatory efficiency (VE/VCO₂) capture integrated mitochondrial function during demand
• 31P-MRS cardiac spectroscopy: PCr/ATP ratio is the gold standard for in vivo cardiac mitochondrial energetics (available at specialised centres)
• Organic acid testing: methylmalonate, 3-hydroxy fatty acids, and Krebs cycle intermediates reflect mitochondrial metabolic flux
• NT-proBNP / high-sensitivity troponin: in cardiac indications, functional improvement typically accompanies biomarker reduction
• PROMIS fatigue scale and 6MWT: patient-reported and functional endpoints sensitive to mitochondrial myopathy improvement

Baseline testing before initiating SS-31 in a clinical protocol should include: comprehensive metabolic panel, CK, LDH, serum lactate, urinalysis, NT-proBNP (if cardiac indication), and echocardiography.

SS-31 in Context: The Integrative Medicine Perspective

In integrative and functional medicine practice, patients presenting with treatment-resistant fatigue, post-viral syndromes, cardiometabolic disease, and accelerated aging frequently show converging evidence of mitochondrial compromise — on organic acid testing, on CPET, and clinically through exercise intolerance disproportionate to structural disease.

SS-31 represents an emergent tool for this population. It is investigational, not yet commercially available, and currently accessible primarily through clinical trials or compassionate use frameworks. However, the mechanistic clarity — a peptide that physically repairs the most energy-dense membrane in the cell — makes it one of the more intellectually compelling agents in the mitochondrial medicine space.

Stacking considerations:

• With NAD+ IV or NMN: provides substrate (NAD+) to feed an ETC that SS-31 has structurally restored — logical combination
• With CoQ10 / ubiquinol: CoQ10 shuttles electrons between complexes whose assembly SS-31 supports; synergistic in theory
• With peptides TB-500 or BPC-157: no known interaction; parallel anti-inflammatory pathways may be additive in tissue repair contexts
• With GLP-1 agonists: GLP-1 has independently demonstrated mitochondrial protective effects in cardiomyocytes; combination rationale exists but is unstudied

Related Articles

• Humanin: The Mitochondria-Derived Peptide for Aging and Metabolic Protection
• MOTS-c: The Mitochondrial Peptide Regulating Metabolism and Exercise Performance
• CoQ10 for Heart Health: Ubiquinol vs Ubiquinone Clinical Evidence
• NAD+ IV Therapy: What to Expect and Who Benefits Most
• Mitochondrial Dysfunction Protocols: Diagnosis and Treatment in Integrative Practice

References

1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050. PMID: 24116962
2. Butler J, Khan MS, Anker SD, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial. Eur J Heart Fail. 2020;22(5):823–833. PMID: 32043674
3. Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9(2):e002206. PMID: 26819376
4. Karaa A, Bertranpetit L, Bhatta N, et al. Long-term open-label extension study of elamipretide in patients with primary mitochondrial myopathy. Neurology. 2024;102(6):e209079. PMID: 38382022
5. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017–2028. PMID: 24134698
6. Whitson JA, Johnson MS, Martin-Perez M, et al. SS-31 rewires the mitochondrial proteome to restore electron transport chain supercomplex assembly and function. Cell Rep. 2021;34(8):108802. PMID: 33626354
7. Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics. 2009;10:388. PMID: 19682365